The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Janus Henderson Global Life Sciences I JFNIX
- NAV / 1-Day Return 75.20 / −0.11 %
- Total Assets 5.2 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.770%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1.0 Mil
- Status Open
- TTM Yield 0.15%
- Turnover 34%
USD | NAV as of Mar 28, 2024 | 1-Day Return as of Mar 28, 2024, 11:46 PM GMT+0
Morningstar’s Analysis JFNIX
Will JFNIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 35.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
UnitedHealth Group Inc | 6.45 | 317.3 Mil | Healthcare |
Eli Lilly and Co | 5.12 | 251.8 Mil | Healthcare |
Novo Nordisk A/S Class B | 4.21 | 207.1 Mil | Healthcare |
AstraZeneca PLC | 3.96 | 194.9 Mil | Healthcare |
Merck & Co Inc | 3.11 | 153.3 Mil | Healthcare |
Sanofi SA | 2.66 | 130.8 Mil | Healthcare |
Abbott Laboratories | 2.65 | 130.3 Mil | Healthcare |
AbbVie Inc | 2.60 | 128.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.35 | 115.7 Mil | Healthcare |
Novartis AG ADR | 2.32 | 114.4 Mil | Healthcare |